Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French Multicentre GEFPICS* Study
- 24 March 2003
- journal article
- research article
- Published by Wiley in Histopathology
- Vol. 42 (4) , 337-347
- https://doi.org/10.1046/j.1365-2559.2003.01598.x
Abstract
Aims: HER2 protein is over‐expressed in 15–30% of breast carcinomas. Immunohistochemistry (IHC) is a common and inexpensive method able to specifically detect HER2 protein. However, lack of standard...Keywords
This publication has 20 references indexed in Scilit:
- HER-2/neu Analysis in Archival Tissue Samples of Human Breast Cancer: Comparison of Immunohistochemistry and Fluorescence In Situ HybridizationJournal of Clinical Oncology, 2001
- Recommendations for HER2 testing in the UKJournal of Clinical Pathology, 2000
- Assessment of Methods for Tissue-Based Detection of the HER-2/neu Alteration in Human Breast Cancer: A Direct Comparison of Fluorescence In Situ Hybridization and ImmunohistochemistryJournal of Clinical Oncology, 2000
- Strong Correlation between Results of Fluorescent In Situ Hybridization and Immunohistochemistry for the Assessment of the ERBB2 (HER-2/neu) Gene Status in Breast CarcinomaLaboratory Investigation, 2000
- Prognostic Factors in Breast CancerArchives of Pathology & Laboratory Medicine, 2000
- Specificity of HercepTest in Determining HER-2/neu Status of Breast Cancers Using the United States Food and Drug Administration–Approved Scoring SystemJournal of Clinical Oncology, 1999
- Immunohistochemical Assays for HER2 OverexpressionJournal of Clinical Oncology, 1999
- Increased HER2 With U.S. Food and Drug Administration-Approved AntibodyJournal of Clinical Oncology, 1999
- Stability of HER-2/neu Expression Over Time and at Multiple Metastatic SitesJNCI Journal of the National Cancer Institute, 1993
- An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinomaBritish Journal of Cancer, 1988